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Summary Clinical anti-tumour efficacy of anti-cancer drugs is a function of dose intensity, i.e. the
concentration-time profile in tumour tissue. Hence, information on drug concentration profiles in tumours is
ofcritical importance but appropriate methods for measurement are lacking. The aim of the present study was
to obtain, by microdialysis sampling, concentration-time profiles in a solid tumour (melanoma) of a model
anti-cancer drug, carboplatin, and thereby to assess the scope of microdialysis for tumour pharmacokinetic
studies in man. Six patients with cutaneous melanoma metastases at the extremities or body trunk, scheduled to
receive carboplatin (400 mg m 2 i.v.) were studied. Carboplatin concentrations were monitored in serum,
intratumoral and subcutaneous tissue. Calibration of the microdialysis probes was carried out in vitro and in
vivo with use of the retrodialysis method. Complete carboplatin concentration vs time profiles in tumour and
subcutaneous tissue were obtained. Major pharmacokinetic parameters (maximum concentration, time to
maximum concentration, area under the curve, elimination half-life) were calculated for tissues and tumour/
serum concentration ratios for carboplatin were derived. Mean free concentrations ofcarboplatin in cutaneous
melanoma metastases reached only about 50-60% of total serum levels; maximal intratumoral concentrations
were 7.6 (±2.0; s.e.m.) Mg ml-', mean concentrations in subcutaneous tissue were similar to those in tumour.
The present study demonstrates that microdialysis is a novel tool for measuring drug concentrations in solid
tumours in humans in vivo and appears to be a valuable addition for pharmacokinetic/pharmacodynamic
studies in oncology.
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It is generally agreed that clinical anti-tumour efficacy ofanti-
cancer drugs is a function of dose intensity, which is defined
as the product of concentration (c) of a cytotoxic drug at the
effect site and the time of cell exposure (t). Under in vitro
conditions dose intensity is easily controlled; however, this is
not the case in a clinical setting, when solid tumours are
treated: the dose rate, i.e. total dose administered per time
period is not necessarily correlated with the dose intensity in
tumour cells (Jain, 1994; Eskey et al., 1992). This lack of
correlation is partly due to interindividual variability of
pharmacokinetics of cytotoxic drugs, in that a given drug
dose may yield highly variable plasma concentrations in
individual patients (De Conti et al., 1973). Nevertheless, even
the plasma concentration-time profile is not necessarily a
measure of the concentration-time profile at the target site,
i.e. in the vicinity of tumour cells: local drug concentrations
within the tumour are not only determined by plasma
concentrations but also by the distribution from the central
compartment (plasma) into the intracellular compartment
within the tumour. It may be speculated that dose intensity
may even be different for different tumour lesions in the same
patient; this could be due to local differences in perfusion
(Coughlin et al., 1994) or tissue permeability and may lead to
the formation of 'tumour cell sanctuaries'. Lack of
accessibility of cytotoxic drugs may play a role in clinical
resistance of tumours to these agents (Skipper, 1965).
Data on intratumoral concentrations of anti-cancer drugs
are rare and are only available from biopsy studies (Hecquet
et al., 1986; Los et al., 1993; Fujiwara et al., 1988; Vaden et
al., 1993), which cannot yield sufficient data on the time
profile of exposure. However, information on drug concen-
tration profiles in tumour tissue is necessary to optimise
dosing and administration schedules, to select novel cytotoxic
compounds with favourable tumour penetration character-
istics and may help explain drug resistance in some patients.
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Recently, the microdialysis technique, based on diffusion
of analytes from the interstitial compartment through a
semipermeable membrane, has been described for in vivo
measurement of drug concentrations in the extracellular fluid
(ECF) space in human tissues (Lonnroth et al., 1991; Stahle
et al., 1991; Scheyer et al., 1994; Muller et al., 1995a). The
aim of this study was to obtain concentration-time profiles
in the ECF of solid tumours of a model anti-cancer drug,
carboplatin, and thereby to assess the scope of microdialysis
for tumour pharmacokinetic studies in man.
Patients and methods
Patients
Six platinum-naive patients (four female, two male, mean age
58+3.6 years, WHO performance status<2) with metastatic
malignant melanoma were included. All patients had
cutaneous malignant melanoma metastases at the extremities
or body trunk accessible to the microdialysis probe and were
already scheduled to receive carboplatin (400 mg m-2)
intravenously as a single agent. Admission of patients to
the study was limited to the first carboplatin cycle.
Concomitant medication included hydration, antiemetic and
diuretic medication; other concomitant medication was
continued.
Study protocol
The study protocol was approved by the ethics committee of
the Vienna University Hospital. Written informed consent
was obtained from all patients before study entry. Patients
remained in a supine position throughout the study period.
Room temperature was kept at 25°C. A plastic cannula
(Venflon) was inserted into an antecubital vein to monitor
serum concentrations of platinum at frequent intervals. The
skin at the site of probe insertion was cleaned and
disinfected. One dialysis probe was inserted intratumorally
into a suitable cutaneous melanoma metastasis and a second
probe was inserted into healthy subcutaneous connective
tissue within a 10- 15 cm distance to the first microdialysisprobe. After the insertion of both microdialysis probes there
was a 30 min equilibration period (Muller et al., 1995a);
subsequently one 15 min microdialysis sample was taken
(baseline level). Thereafter, carboplatin (400 mg m-2) was
infused intravenously through a second cannula over a time
period of 20 min. Sampling of microdialysates and blood
were performed in 15 min intervals for up to 4 h, blood
samples were taken at mid-time points of each microdialysis
collection period.
Microdialysis procedure
The principles of microdialysis have been described in detail
previously (Ungerstedt, 1991; L6nnroth et al., 1987;
Morrison et al., 1991). Briefly, microdialysis is based on
sampling of analytes from the extracellular space by diffusion
through a semipermeable membrane. This process is
accomplished in vivo by using a microdialysis probe, which
is constantly perfused with a physiological solution at a low
flow-rate (0.5-10 ,ul min-m). Once the probe is implanted into
the tissue, substances are filtered by diffusion from the
extracellular fluid into the perfusion medium. Samples are
collected and analysed.
In our experimental procedures, a commercially available
microdialysis probe (CMA 10, CMA, Stockholm, Sweden)
with a molecular cut-off of 20 kDa, an outer diameter of 500
,um and a membrane length of 16 mm was used. Dialysis
probes were inserted into a cutaneous melanoma metastasis
and into nearby subcutaneous tissue by the following
procedure. The surface of the disinfected skin was punctured
vertically by a 20 gauge i.v. plastic cannula. The steel
mandrin was removed. After an aspiration check (to confirm
that the tip of the probe was not positioned in a blood vessel)
the microdialysis probe was inserted into the plastic cannula.
The plastic cannula was removed, leaving the probe under the
surface of the skin. The proper position of the probe in the
tumour was confirmed by high frequency (7.5 MHz)
ultrasound scanning (Figure 1). No local anaesthesia was
used. The second microdialysis probe was inserted horizon-
tally into the subcutaneous connective tissue in an identical
fashion. The microdialysis system was connected and the
probes were perfused by means of a precision infusion pump
(Precidor, Ilfors-AG, Basle, Switzerland) at a constant flow
rate of 1.5 pi min-'). Ringer's solution was used as perfusion
fluid. Perfusate samples for measurement of drug levels were
collected by means of a microfraction collection (CMA 120,
CMA, Stockholm, Sweden) and stored at -20°C before
analysis.
Owing to diffusion and sampling of the dialysate there is a
Figure 1 Two-dimensional ultrasound scan of microdialysis
probe in a melanoma lesion. The position of a microdialysis
probe is established by high frequency (7.5 MHz) scanning. The
tip of the probe (arrow) is clearly positioned in the peripheral
aspects of the circular melanoma lesion.
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certain time delay before sudden concentration changes in the
ambient medium are detected in the microdialysis probe. This
time delay was taken into account for all experiments.
Assessment ofprobe recovery
In vitro experiments To characterise the transfer rate of the
probes we assessed in vitro recovery of carboplatin. The
dialysis probe was placed in glass beakers containing different
concentrations of carboplatin. The probe was perfused at a
flow rate of 1.5 MI min-'. Analyte concentrations were
measured in the dialysate and expressed as percentage of the
concentration in the surrounding medium. There was a linear
correlation between carboplatin concentrations in the
dialysate and drug concentrations in the surrounding
medium over a wide concentration range. In vitro recovery
at 20'C was 64% (r>0.95).
In vivo experiments In vivo recovery of carboplatin was
assessed according to the retrodialysis method (Stahle et al.,
1991, Palmsmeier et al., 1994). The principle of this method
relies on the assumption that the diffusion process is
quantitatively equal in both directions through the semi-
permeable membrane. Therefore, carboplatin was added to
the perfusion medium ('perfusate') and the disappearance
rate through the membrane was calculated and taken as a
measure of in vivo recovery. Thus, the in vivo recovery value
was calculated as:
Recovery (%) =
100 - (100 x carboplatindialysate xcarboplatinperffimte 1)
where carboplatindialyate is the carboplatin concentration in
the dialysate and carboplatin fmraute is the carboplatin
concentration in the perfusate.
In vivo recovery was assessed on separate study days by
dialysing the tumour tissue with a perfusion medium
containing 8 Mug ml-1 carboplatin for 120 min.
Study drug
Carboplatin (Paraplatin, Bristol-Myers Squibb, Mayaguez,
Puerto Rico) was administered as a single intravenous dose of
400 mg m-2, infusion time was 20 min.
Analysis
Platinum concentrations in serum and in the perfusate were
measured by atomic absorption spectroscopy as described
previously (McGahan et al., 1987).
Data analysis and calculations
All data are presented as means+s.e.m. Coefficients of
variation (CVs) were calculated as 100 s.d. mean-'.
Intercellular tissue concentrations were calculated by the
following formula:
Tissue concentration =
100 x dialysate concentration x in vivo recovery value'
Maximal carboplatin concentrations (cma) were obtained
from direct inspection of the concentration time curves. The
time of maximal concentration (tmax) was defined as the time
after start of the infusion at which cm. occurred.
The terminal half-life of elimination (t/2el) from serum,
tumour and subcutaneous tissue was calculated by a direct fit
(non-linear computer-assisted iteration) according to the least
squares curve fitting equation describing a monoexponential
decay (using a Gauss-Newton algorithm).
Areas under the curve from 0 to 4 h (AUCO 4h) wereMicrodialysis in oncology
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calculated for serum (AUCSeTUJX), tumour (AUCtumIour) and
subcutaneous tissue (AUCSc), using the trapezoidal rule.
Penetration ratio of carboplatin into tumour and subcuta-
neous tissue was quantified by the ratio of AUCtumour!
AUCserum, and AUCsc/AUCseum respectively.
As pharmacokinetic parameters were non-normally dis-
tributed, statistical comparisons between compartments
(serum, tumour, subcutaneous tissue) were made by the
Wilcoxon matched paired test. Correlations between para-
meters from different compartments were calculated employ-
ing Spearman rank order correlations (rj). Furthermore,
linear regression analyses were performed. P<0.05 was
considered the level of significance.
Results
Microdialysis experiments were well tolerated by all patients,
there were no adverse events such as bleeding or pain at the
site of probe insertion.
In vivo recovery measurements
Mean in vivo recovery values of carboplatin measured by the
retrodialysis method at 37°C was 84% for tumour and 74%
for subcutaneous tissue.
Serum, tumour and subcutaneous tissue pharmacokinetics
The time vs concentration curves for carboplatin obtained by
in vivo sampling in serum, tumour and subcutaneous tissue
are shown in Figure 2. Key pharmacokinetic parameters are
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Figure 2 Concentration profile of carboplatin in serum, tumour
and subcutaneous tissue. Results are presented as mean values +
s.e.m. from six patients. Time 0 is the time of the start of the
carboplatin infusion (horizontal arrow). -0-, Serum; -A-,
tumour; -U-, subcutaneous.
presented in Table I. Mean Cmax/Cmaxserum ratio was 0.51 +0.10
(CV =49%); mean Cmaxsc/Cmaxserum ratio was 0.42+0.12
(CV=70%). Mean AUCt,,lour/AUCserun ratio was 0.58+0.10
(CV=42%) and mean AUCSC/AUCSrUT, ratio was 0.41+0.13
(CV -=78%).
Mean Cmax and AUC levels in tumour and subcutaneous
tissue were significantly lower than in serum (Table I); there
was no statistically significant difference in cmax or AUC
between tumour and subcutaneous tissue (P=0.75 and
P = 0.25 respectively).
There was no correlation between AUCserum and AUCt.XU
(r, =0.66, P, =0.16), between Cmaxserl,, and Cmax-tumour (r, =0.26,
Ps 0.62), or between AUCserum and cmax tumour (r,=0.43,
PS=0.40). Linear regression analyses are shown in Figure 3.
Discussion
This study constitutes the first description, to our knowledge,
of a complete pharmacokinetic profile of a cytotoxic agent in
a human tumour. Microdialysis sampling permitted the
estimation of key pharmacokinetic parameters (cmax, tmax,
t/2e1 AUC) in the ECF space of tumour and subcutaneous
tissue. By relating tissue data to serum pharmacokinetics, the
distribution kinetics of carboplatin into the target lesion, i.e.
the tumour, could be characterised much more precisely than
by estimation from serum concentrations alone.
Mean AUC and cma,, values in the tumour-ECF reached
only about 50-60% of the corresponding values in serum
(Table I, Figure 2), this indicates rapid but incomplete
equilibration between blood and the intracellular tumour
compartment. Similar results were obtained from subcuta-
neous tissue, although mean AUC and cmax values were
slightly but non-significantly lower than for tumour.
It is also useful to consider the degree of between-patient
variability of our measurements. For a given dose, the extent
to which a solid tumour or non-malignant tissue is exposed
to the cytotoxic drug is a function ofplasma levels and of the
extent to which the drug equilibrates between the plasma and
the ECF space of the tissue. Hence, between-patient
variability in tissue exposure is determined by the combined
variabilities in plasma levels and tissue distribution. Whereas
intersubject variability in plasma levels is readily assessed
from classic pharmacokinetic data, there is very little
information on variation regarding the distribution process.
In our study the variability in serum concentrations is
reflected by the coefficient of variation (CV) of cmax-serum
values, which was 18% for carboplatin. On the other hand,
variability associated with the distribution process into
tumour and subcutaneous tissue can be quantified by the
CV of the Cmaxtumour/cmax-rerum ratio and the Cmax-scdcmax-serum
ratio, which was 49% and 70% respectively, in our patient
group. This is also borne out by the lack of correlation
between serum- and tumour- or subcutaneous-AUC and cm,,x
levels in our patients, which indicates that serum pharmaco-
kinetic parameters are poor predictors of carboplatin
Table I Key pharmacokinetic parameters from serum, tumour intercellular space and subcutaneous tissue intercellular space after carboplatin
infusion (400 mg m-2 over 20 min, i.v.). Results are expressed as means+ s.e.m. from six patients. Numbers in brackets indicate coefficient of
variation
Serum Tumour Subcutaneous
Cmax (Pg ml ') 14.6+ 1.1 7.6+2.0* 5.6+ 1.2*
(CV%) (17.7) (64.5) (52.8)
tmax (min) 34+ 5 60± 10 54±7
(CV%) (35.3) (41.7) (33.3)
t/2ei (min) 90±6 99±20 91 ±23
(CV%) (16.7) (49.5) (62.6)
AUC (pg ml-' min) 1533 + 189 853+ 172* 506+ 87*
(CV%) (30.1) (49.4) (42.1)
cma, maximal carboplatin concentration; tmax, time after start ofinfusion at which cmax occurred; t/2e1, terminal elimination half-life;AUC, area
under the time vs concentration curve from 0 to 4 h. * P< 0.05 vs serum.
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r= 0.50, P = 0.31 highlighting the importance of differences in tumour vascular architecture (Jain, 1988, 1994). Clearly, the information
obtained with the placement of one microdialysis probe
need not be representative for the whole tumour; this may be
regarded as a limitation of our study. However, wherever
possible, we have attempted to position the probe tip in the
peripheral, presumably well perfused aspects, of melanoma
M M lesions. While placement of more than one probe per tumour
* might be more informative, this is precluded by ethical and
technical reasons.
Our microdialysis data also allow for the estimation of the
elimination half-life of carboplatin in the tumour, which is a Iz 1200 1500 1800 2100 tU~l~llO~l OI me pam a cnA ana m ue l'nfv
0 900 1200 1500 1800 2100 characteristics of the drug under study. For carboplatin, t/2"1 AUC serum (jig ml min) in tumour was similar to t/2e, in serum (Table I). Again, this
is in agreement with in vitro studies showing that, perhaps
owing to its comparatively low reactivity with proteins,
carboplatin is not strongly and irreversibly bound to tumour
tiq'qlle Mnc-nllpt 'Pt nl 19aqu
Some methodological aspects of our study deserve
discussion: One important aspect of microdialysis concerns
the relationship between absolute ECF concentrations and
dialysate concentrations. The results of our in vitro
calibration experiments clearly show that the process of
carboplatin diffusion through the microdialysis membrane is
concentration independent over a wide range of concentra-
tions. Similar observations have been reported for an array of
different analytes (Ldnnroth et al., 1987; Jansson et al., 1993).
Nevertheless, although characterisation of relative changes in
ECF concentration is readily feasible by means of micro-
dialysis, measurement of absolute ECF concentration may
noe nrnhlem hecr-imve rercverv nf the mi rnAlcvc nrnhe. ie. 0 10 15 20 PIva a1pivuiwul uvaual;-qlWvq9iYVI~}U L1IF. lllunLavumibio CORvuS
i
incomplete. However, reliable calibration techniques are Cmax serum (ig mlF) available to obtain absolute, 'true' ECF concentrations. In
particular, the retrodialysis technique was shown to be
valuable in animal and human drug studies with micro-
dialysis when no steady state of the analyte is reached
20 - (Stahle, 1991; Palsmeier, 1994; Muller et al., 1995a). We have
r=0.53, P = 0.28 shown that retrodialysis is also feasible in solid tumours.
0 While microdialysis measures free drug concentration in
15 the ECF compartment of target tissue, we have only
measured total (i.e. free and protein-bound) platinum
concentration in serum. For many drugs, only the free
10 _ fraction is available for equilibration with peripheral tissues.
For carboplatin, protein binding is minimal during the first
hours following administration (Fujiwara et al., 1988), but
_ * has been shown to increase over time (Dollery, 1991).
Therefore, we cannot estimate free carboplatin serum
* concentration during the course of our experiments and the
0 A I | 'true' equilibration rate between serum and tumour may be
0 900 1200 1500 1800 2100 slightly higher than is suggested by our AUCtumour/AUCserum
AUC serum (jig ml-1 min) ratios.
It must be emphasised that tumour ECF concentrations,
re 3 Relationship between area under the carboplatin like serum concentrations, represent only an 'intermediate'
entration -time curve (AUC) and maximal carboplatin pharmacokinetic end point and in themselves yield no
entration (cma,,) in serum and tumour intercellular space. information on anti-tumour effect. It will be of interest to
assess, in future studies, the correlation between ECF kinetic
and tumour effect-related end points such as carboplatin
adduct formation.
ntration in tumour and non-malignant tissue ECF. What is the potential utility of microdialysis sampling for
the ECF space within the tumour lesion immediately oncological studies? As we have shown, microdialysis allows
unds tumour cells, ECF concentrations, rather than for the assessment of the concentration profile of anti-cancer
lconcentration, determine the amount ofcytotoxic drug drugs in the tumour ECF space, the medium that immediately
hich tumour cells are exposed. Hence, our data also surrounds tumour cells. Thus, in pharmacokinetic terms, the
st that the lack of correlation between serum ECF space of the tumour may be regarded as the true
ntrations and anti-tumour effect, which has been anatomical 'effect compartment'. Microdialysis offers some
ved for carboplatin and other cytotoxic agents advantages over tumour biopsy sampling, the method
ery, 1991), may not only be a result of differing drug traditionally used to measure tissue drug concentrations.
nsiveness of individual tumours, but also of a highly Microdialysis is well tolerated and causes only moderate pain, 1e and unpredictable tumour distribution, at least for similar to an intramuscular or subcutaneous injection. In
tplatin. contrast, biopsy sampling is invasive, and frequent sampling is
stribution may not only vary between solid tumours, not possible because of ethical considerations, thereby
Iso within the same tumour lesion. For instance, a large precluding assessment of concentration-time courses. On the
Lion in uptake of carboplatin by individual tumour other hand, biopsies can provide information on intracellular,
Rents has been shown in vitro (Hecquet et al., 1986), tumour effect-related end points, e.g. DNA adduct formation.
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The use of rigid steel probes limits the use of microdialysis
to very superficial tumours, such as melanoma as in our
experiments. However, the availability of soft, flexible and
small-diameter probes, which are inserted under ultrasound
guidance, allows for the study even of deep-seated, less
accessible tumour nodules. The duration of a single
microdialysis experiment is limited only by the inconvenience
caused to the experimental subject, particularly the require-
ment of resting in a supine position. However, Bolinder et al.
(1993), reported the use of special microdialysis probes for
long-term studies. Major limitations of the microdialysis
technique are the low recovery for molecules with large
molecular weights or a high lipophilicity (Stahle, 1991;
Carneheim and Stahle, 1991; Pich et al., 1993; Muller et
al., 1995b) and the requirement for sensitive analytical
techniques because of the small sample volumes and low
concentrations obtained by microdialysis.
Microdialysis may also lend itself to the study of local
drug metabolism in tumour tissue, which is of paramount
importance for drug classes such as bioreductive agents
(Palsmeier et al., 1994). In addition, the technique may be
applied to the study of concentration-effect relationships of
anti-cancer agents by measuring the intratumoral release of
local mediators or markers of cell damage.
In conclusion we have demonstrated that microdialysis
sampling is suitable for measuring drug concentrations in the
ECF space of solid tumours in humans. This technique may
become a valuable addition for pharmacokinetic/pharmaco-
dynamic studies in oncology.
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